With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled

With data demonstrating superiority to Humira and likely lower pricing than anti-TNF drugs, baricitinib may be poised to make more of an impact than Pfizer has with its JAK inhibitor Xeljanz.